Department of Ophthalmology, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University and Collaborative Innovation Center, Chengdu, Sichuan, China.
Signal Transduct Target Ther. 2023 Feb 6;8(1):57. doi: 10.1038/s41392-022-01234-1.
The prime editor (PE) can edit genomes with almost any intended changes, including all 12 possible types of base substitutions, small insertions and deletions, and their combinations, without the requirement for double strand breaks or exogenous donor templates. PE demonstrates the possibility of correcting a variety of disease-causing mutations and might expand the therapeutic application of gene editing. In this study, PE was optimized based on a dual-adeno-associated virus (AAV) split-intein system in vitro by screening different split sites and split inteins. We found that splitting PE before amino acid 1105(Ser) of SpCas9 with Rma intein resulted in the highest on-target editing. The orientations of pegRNA and nicking sgRNA in the AAV vector were further optimized. To test the in vivo performance of the optimized dual-AAV split-PE3, it was delivered by subretinal injection in rd12 mice with inherited retinal disease Leber congenital amaurosis. The prime editors corrected the pathogenic mutation with up to 16% efficiency in a precise way, with no detectable off-target edits, restored RPE65 expression, rescued retinal and visual function, and preserved photoceptors. Our findings establish a framework for the preclinical development of PE and motivate further testing of PE for the treatment of inherited retinal diseases caused by various mutations.
主编辑 (PE) 几乎可以对任何预期的变化进行基因组编辑,包括所有 12 种可能的碱基替换类型、小插入和缺失及其组合,而无需双链断裂或外源供体模板。PE 展示了纠正多种致病突变的可能性,并可能扩展基因编辑的治疗应用。在这项研究中,我们通过筛选不同的分裂位点和分裂内含子,在体外基于双腺相关病毒 (AAV) 分裂内含子系统对 PE 进行了优化。我们发现,在 SpCas9 的氨基酸 1105(Ser)之前用 Rma 内含子将 PE 分裂,可获得最高的靶向编辑。进一步优化了 AAV 载体中 pegRNA 和切口 sgRNA 的取向。为了测试优化后的双 AAV 分裂 PE3 的体内性能,它通过视网膜下注射递送至具有遗传性视网膜疾病莱伯先天性黑矇的 rd12 小鼠中。主编辑器以高达 16%的效率精确地纠正了致病性突变,没有检测到脱靶编辑,恢复了 RPE65 的表达,挽救了视网膜和视觉功能,并保留了光感受器。我们的研究结果为 PE 的临床前开发建立了框架,并促使进一步测试 PE 治疗由各种突变引起的遗传性视网膜疾病。